A Phase 1 interventional study of Dapiglutide 7.5 mg in Overweight and Obesity, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 336 studies in Obesity with a site in Germany — 73 open to participants now, 108 under way, 47 of them phase 3. Obesity · Germany.
Among the 336 studies in Obesity with a site in Germany, this one is the 244th largest by enrollment of the 274 interventional ones that give a count, is one of 22 that started in 2024, is one of 43 in phase 1, and was the 250th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →73 of the 336 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Brazil and 7 more countries
Ages 18+
German Diabetes Center · Sites in Germany
Ages 19–75
Technical University of Munich · Sites in Germany
Ages 18–60
Novo Nordisk A/S · Sites in Germany
Ages 18+
Boehringer Ingelheim · Sites in Germany
Ages 18–74
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
336 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 27 · Phase 3 87 · Phase 4 12
First in 1998; this study’s year is marked. 22 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 156 across the 274 interventional studies, 165 across the 62 observational. Of the 198 that completed or were terminated, 32 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 336 have an industry lead sponsor. The 10 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
38 of the studies in Obesity with a site in Germany that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
Add all 38 to your calendar (.ics) → With an account.
Among the 336 studies in Obesity with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL. The trial will be conducted in participants with a BMI ≥ 27.0 kg/m2.
Dapiglutide is a dual Glucagon-like peptide-1-/Glucagon-like peptide-2 Receptor Agonist (GLP-1R/GLP-2RA) in clinical development for weight management. The purpose of this phase 1 trial is to compare pharmacokinetics (PK) of a single dose administration of 7.5 mg dapiglutide administered subcutaneously (s.c.) with two drug product concentrations, 10 mg/mL and 25 mg/mL and will be conducted in 30 participants with a body mass index (BMI) ≥ 27.0 kg/m2. The development of a drug product with higher drug concentration will facilitate investigation of a wider dose range of dapiglutide in the clinical development program of the compound. The PK profile of a weight management drug should be assessed in people with a wide range of BMI and with a BMI within the range of the target population as body weight is expected to influence PKs of dapiglutide.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 30 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose, s.c. administration
Drug: Dapiglutide 7.5 mg
Single dose, s.c. administration
Drug: Dapiglutide 7.5 mg
Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.
To compare pharmacokinetics of a single dose administration of 7.5 mg dapiglutide
Area under the dapiglutide plasma concentration-time curve from time zero to infinity after a single 7.5 mg dose of dapiglutide (AUC0-inf).
Time frame: Trial Day 1 to 28
To compare pharmacokinetics of a single dose administration of 7.5 mg dapiglutide
Maximum observed dapiglutide plasma concentration after a single 7.5 mg dose of dapiglutide (Cmax)
Time frame: Trial Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Area under the dapiglutide plasma concentration-time curve from time zero to last measurable concentration after a single 7.5 mg dose of dapiglutide (AUC0-t)
Time frame: Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Time to maximum observed dapiglutide plasma concentration after a single 7.5 mg dose of dapiglutide (Tmax)
Time frame: Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Terminal elimination half-life for dapiglutide after a single 7.5 mg dose of dapiglutide (t½)
Time frame: Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Elimination rate constant for dapiglutide after a single 7.5 mg dose of dapiglutide (λz)
Time frame: Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Apparent clearance of dapiglutide after a single 7.5 mg dose of dapiglutide (CL/F)
Time frame: Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Apparent volume of distribution during terminal phase of dapiglutide after a single 7.5 mg dose of dapiglutide (Vz/f)
Time frame: Day 1 to 28
To characterize the pharmacokinetic profiles of a single dose administration of 7.5 mg dapiglutide
Mean residence time of dapiglutide after a single 7.5 mg dose of dapiglutide (MRT)
Time frame: Day 1 to 28
To investigate the safety and tolerability of a single dose administration of 7.5 mg dapiglutide
Incidence of treatment emergent adverse events (TEAEs) from dosing (Day 1) to end of trial (Day 42).
Time frame: Day 1 to 42
Plan to share: No — The data collection and handling of clinical trial data at the trial site has been designed to limit the possibility of identifying trial subjects from their data. To this end, pseudonymised data will be used wherever possible and the collection of demographic information that could be used for re-identification of subjects will be restricted to the extent necessary for the conduct of this trial.
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Apr 2025, 3 months.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapiglutide